Immunogenicity of Therapeutic Proteins

5Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The use of proteins for medical applications has revolutionized therapies of many diseases/disorders that were often incurable with small-molecule medicines. However, since the first use of proteins as medicines, their immunogenicity has been a major problem. Over the years the quality and safety of therapeutic protein products have improved dramatically. Nevertheless, even the protein medicines of the newest generation may still cause adverse immunological events, posing a safety risk for patients and/or compromising their efficacy. Immunogenicity of therapeutic proteins is a complex, multifactorial phenomenon. In this chapter we summarize the current knowledge about immune mechanisms underlying the immunogenicity of therapeutic proteins and discuss influencing factors and clinical consequences of protein immunogenicity as well as strategies for immunogenicity assessment and mitigation.

Cite

CITATION STYLE

APA

Jiskoot, W., Rispens, T., & Kijanka, G. (2019). Immunogenicity of Therapeutic Proteins. In Pharmaceutical Biotechnology: Fundamentals and Applications (pp. 139–150). Springer International Publishing. https://doi.org/10.1007/978-3-030-00710-2_7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free